Arcellx, Inc.

54.98 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arcellx, Inc. stock is up 23.19% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 December’s closed higher than November. In the last 3 Unusual Options Trades, there were 3 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
26 Oct 17:43 15 Dec, 2023 35.00 CALL 400 5
14 Nov 15:17 17 May, 2024 35.00 CALL 20 15
17 Nov 16:57 17 May, 2024 35.00 CALL 28 28

About Arcellx, Inc.

Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.

  • HC Wainwright & Co.
    Wed Nov 15, 13:47
  • Needham
    Wed Nov 15, 13:34